Download
s00392-020-01740-8.pdf 2,06MB
WeightNameValue
1000 Titel
  • Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
1000 Autor/in
  1. Katzmann, Julius L. |
  2. Sorio-Vilela, Francesc |
  3. Dornstauder, Eugen |
  4. Fraas, Uwe |
  5. Smieszek, Timo |
  6. Zappacosta, Sofia |
  7. Laufs, Ulrich |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-09-19
1000 Erschienen in
1000 Quellenangabe
  • 111(3):243-252
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00392-020-01740-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873069/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Many patients at very-high atherosclerotic cardiovascular disease risk do not reach guideline-recommended targets for LDL-C. There is a lack of data on real-world use of non-statin lipid-lowering therapies (LLT) and little is known on the effectiveness of fixed-dose combinations (FDC). We therefore studied prescription trends in oral non-statin LLT and their effects on LDL-C.!##!Methods!#!A retrospective analysis was conducted of electronic medical records of outpatients at very-high cardiovascular risk treated by general practitioners (GPs) and cardiologists, and prescribed LLT in Germany between 2013 and 2018.!##!Results!#!Data from 311,242 patients were analysed. Prescriptions for high-potency statins (atorvastatin and rosuvastatin) increased from 10.4% and 25.8% of patients treated by GPs and cardiologists, respectively, in 2013, to 34.7% and 58.3% in 2018. Prescription for non-statin LLT remained stable throughout the period and low especially for GPs. Ezetimibe was the most prescribed non-statin LLT in 2018 (GPs, 76.1%; cardiologists, 92.8%). Addition of ezetimibe in patients already prescribed a statin reduced LDL-C by an additional 23.8% (32.3 ± 38.4 mg/dL), with a greater reduction with FDC [reduction 28.4% (40.0 ± 39.1 mg/dL)] as compared to separate pills [19.4% (27.5 ± 33.8 mg/dL)]; p < 0.0001. However, only a small proportion of patients reached the recommended LDL-C level of < 70 mg/dL (31.5% with FDC and 21.0% with separate pills).!##!Conclusions!#!Prescription for high-potency statins increased over time. Non-statin LLT were infrequently prescribed by GPs. The reduction in LDL-C when statin and ezetimibe were prescribed in combination was considerably larger for FDC; however, a large proportion of patients still remained with uncontrolled LDL-C levels.
1000 Sacherschließung
lokal Anticholesteremic Agents/administration
lokal Aged [MeSH]
lokal Cardiovascular disease
lokal Drug Prescriptions/statistics
lokal LDL cholesterol
lokal Fixed-dose combination
lokal Cholesterol, LDL/drug effects [MeSH]
lokal Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration
lokal Male [MeSH]
lokal Ezetimibe/administration
lokal Hypercholesterolemia/drug therapy [MeSH]
lokal Drug Therapy, Combination [MeSH]
lokal Statin
lokal Female [MeSH]
lokal Humans [MeSH]
lokal General Practice/statistics
lokal Treatment Outcome [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Cross-Sectional Studies [MeSH]
lokal Time Factors [MeSH]
lokal Adherence
lokal Atherosclerosis/drug therapy [MeSH]
lokal Germany [MeSH]
lokal Original Paper
lokal Practice Patterns, Physicians'/statistics
lokal Ezetimibe
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-2457-1129|https://frl.publisso.de/adhoc/uri/U29yaW8tVmlsZWxhLCBGcmFuY2VzYw==|https://frl.publisso.de/adhoc/uri/RG9ybnN0YXVkZXIsIEV1Z2Vu|https://frl.publisso.de/adhoc/uri/RnJhYXMsIFV3ZQ==|https://orcid.org/0000-0003-1681-9777|https://frl.publisso.de/adhoc/uri/WmFwcGFjb3N0YSwgU29maWE=|https://orcid.org/0000-0003-2620-9323
1000 Hinweis
  • DeepGreen-ID: 3bdfb3c06c404946bdf6af8712de84f3 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6469948.rdf
1000 Erstellt am 2023-11-18T02:49:31.416+0100
1000 Erstellt von 322
1000 beschreibt frl:6469948
1000 Zuletzt bearbeitet Fri Dec 01 10:51:48 CET 2023
1000 Objekt bearb. Fri Dec 01 10:51:48 CET 2023
1000 Vgl. frl:6469948
1000 Oai Id
  1. oai:frl.publisso.de:frl:6469948 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source